How Pharma Brands Get Inside the AI Answer Box

SATELLITE · THE PHARMA PILLAR

Part of the Everything-PR Pharma Pillar · Pharma Source-Layer cluster: The Mylan EpiPen Pricing Crisis · WebMD Is Losing to Reddit on Drug Questions · How Hims, Ro & Telehealth Built the New Drug Marketing

Updated June 6, 2026 · By EPR Editorial Team

Pharma is the consumer category with the highest AI refusal rate. It is also the category where the source layer is the most rigorously regulated, the most heavily documented, and the most stable over time. The combination produces a pharma AI landscape unlike any other.

When a buyer asks an AI engine about a drug, a condition, a side effect, or a treatment option, the engines exhibit two patterns simultaneously: high refusal rates on specific medical questions (out of regulatory caution), and high citation concentration on the answers they do return — drawn from the FDA, NIH, Mayo Clinic, Drugs.com, PubMed, and a narrow set of authoritative medical references. The brands that surface in those answers are the brands with documented, regulator-approved, peer-reviewed primary records.

In pharma, the FDA, NIH, Mayo Clinic, and Drugs.com effectively run the answer. The brands cited are the brands with documented, FDA-approved, peer-reviewed primary records. Compliance is AI visibility.

This piece maps the pharma source layer, examines one major case study, and lays out the playbook. The full framework — the AI Visibility Stack, the retrieval pipeline, and the methodology — lives in the hub: How to Get Inside the ChatGPT Answer Box.

Why Pharma Is Different

Pharma sits at the intersection of medicine, regulatory disclosure, scientific publication, insurance reimbursement, and consumer health-seeking behavior. It is the consumer category where the FDA, the NIH, and major medical reference sites (Mayo Clinic, Drugs.com, UpToDate) carry institutional weight that no other category replicates. AI engines weight those sources accordingly.

It is also the category where the brand-vs-generic naming dynamic shapes AI answers in a way nothing else does. When AI engines describe a class of medication, they may use the generic compound name (atorvastatin, metformin, semaglutide), the brand name (Lipitor, Glucophage, Ozempic), or both — and which one surfaces correlates strongly with documentation depth, Wikipedia presence, and named-entity density across the medical reference layer.

The Pharma Source Map

The pharma source layer is the most concentrated of any consumer category. The top 10 sources capture roughly 75% of every modeled pharma AI answer. FDA-published documents lead. Peer-reviewed research (PubMed) sits second. Major medical reference sites carry the middle of the chart. Brand-direct content appears far below.

Methodology, up front: we prompted five engines (ChatGPT, Claude, Perplexity, Gemini, Google AI Overviews) with 60+ pharma-research buyer prompts spanning drug efficacy framing, side effect questions, condition-treatment options, drug-class comparisons, and prescription-vs-OTC decisions, then manually coded recurring source appearances in the generated answers. We also tracked refusal rate per prompt category, which is uniquely high in pharma. Q2 2026 prompt sweep. Estimated share of recurring sources, not platform-reported data. Full methodology below the chart.

Estimated share of recurring source appearances across 60+ pharma-research buyer prompts. Not platform-reported data. Full methodology below.

Four patterns stand out.

Regulator-published sources lead pharma AI. FDA.gov (including drugs@FDA, the FDA Drug Approval Database, and the FDA Adverse Event Reporting System) plus NIH MedlinePlus together supply roughly 21% of every modeled pharma AI answer. No other consumer category sees regulator-published primary sources at this weight. AI engines treat FDA and NIH documentation as the authoritative pharma record.

Peer-reviewed research is the second authority. PubMed and UpToDate together supply roughly 16% of modeled pharma answers. AI engines pull from clinical trial publications, systematic reviews, and meta-analyses when buyers ask about efficacy, comparison, or mechanism-of-action questions. Drugs without robust peer-reviewed publication records show systematically lower AI visibility.

The brand-vs-generic dynamic shapes the answer. In modeled queries, AI engines use brand names (Lipitor, Ozempic, Eliquis) more frequently for branded drugs with deep marketing-era documentation, and generic names (atorvastatin, semaglutide, apixaban) more frequently for post-patent or generic-first conversations. The naming choice the AI makes is itself a visibility outcome. Brands that fail to defend their named-entity density during the post-patent transition see their AI mentions migrate to the molecule name.

Brand-direct content underperforms substantially. In modeled pharma queries, brand websites, drug-specific microsites, and patient marketing pages collectively appear at under 4% citation share. Pharma is the category where DTC advertising spend is structurally decoupled from AI visibility. The brands that surface in AI are the brands documented in regulator, scientific, and medical reference sources — not the brands with the largest DTC budgets.

A Compliance Note Before the Case Study

Pharma is the most heavily regulated consumer category in the United States. The FDA governs drug labeling, indications for use, off-label discussion, and direct-to-consumer advertising under the Food, Drug, and Cosmetic Act. The FTC governs efficacy claims and substantiation. State attorneys general add enforcement layers. AI engines exhibit the highest refusal rate on pharma prompts of any consumer category we measure — a direct reflection of this regulatory environment and the engines' own caution settings on medical advice.

The implication for the source-layer playbook: every move in this piece assumes compliance-first execution under FDA, FTC, and state-level requirements. Drug labels must be current. Indications for use must be on-label. Adverse event documentation must be accurate. Clinical trial publication must be substantiated. Brands that pursue AI visibility through off-label suggestion, unsubstantiated comparative claims, or promotional content that violates FDA-OPDP guidance face triple exposure — regulatory penalty, plaintiff litigation, and the AI-citation gap when engines refuse to discuss non-compliant claims.

In pharma, source-layer authority and regulatory compliance are not separate disciplines. They are the same discipline.

How Pfizer Built Pharma AI Dominance

A case study in source-layer construction — and why Pfizer consistently surfaces in AI answers about pharma brands, drug categories, and the pharmaceutical industry overall.

Pfizer is named #1 in EPR's pharma AI citation share research. The architecture that produced this is publicly observable, decades in the making, and instructive for any pharma brand operating in 2026.

The multi-decade FDA documentation layer. Pfizer has filed FDA primary documentation across dozens of approved drugs over decades — Lipitor, Viagra, Lyrica, Eliquis, the Pfizer-BioNTech COVID-19 vaccine (Comirnaty), Paxlovid, and many others. Each approval, labeling update, post-marketing surveillance report, and adverse event filing enters the regulator layer that AI engines weight highest. The cumulative FDA documentation depth across Pfizer's portfolio is among the largest in pharma. In our modeled queries, Pfizer-associated FDA records appear across drug-class, condition-treatment, and pharma-industry prompts.

The Wikipedia entry depth. Pfizer's corporate Wikipedia entry is extensive and primary-source-rich. Wikipedia entries also exist for major drugs (Lipitor, Viagra, Comirnaty), key executives (Albert Bourla, Mikael Dolsten), and historical milestones (the Wyeth acquisition, the Allergan acquisition attempt, the Warner-Lambert acquisition). The named-entity graph linking corporate, drug, executive, and milestone entries is dense across Wikipedia, which AI engines tend to weight as authority. In our research, Pfizer appears named in modeled AI answers even on prompts that did not specifically ask about Pfizer.

The scientific publication record. Pfizer-sponsored clinical trials, post-marketing studies, and academic collaborations have produced thousands of PubMed-indexed publications over decades. Major drug approvals (Lipitor, Comirnaty, Paxlovid) are supported by pivotal Phase III trial publications in NEJM, JAMA, The Lancet, and other top-tier medical journals. AI engines pull from these publications when buyers ask efficacy, comparison, or mechanism questions. The publication depth is itself a competitive moat against challenger pharma brands.

The investor relations and primary corporate documentation. Pfizer's 10-K filings, 10-Q filings, investor presentations, R&D pipeline disclosures, and public earnings transcripts enter the AI retrieval layer as primary documents. AI engines weight primary documents above marketing content. The continuous publication of SEC-required corporate documentation produces a stable, authoritative record AI engines reference.

What AI engines say today. Across modeled queries about pharmaceutical companies, drug categories Pfizer participates in (statins, anticoagulants, vaccines, antivirals), and industry-level pharma questions, Pfizer consistently appears in the AI answer — often named first or second. Competitor mentions (Johnson & Johnson, Merck, AbbVie, Eli Lilly) appear at varying citation share depending on the prompt; Pfizer's consistency across prompts is the distinguishing feature. The architecture is decades in the making: multi-drug FDA documentation + Wikipedia depth + scientific publication record + corporate primary documents.

The balancing signal. Pfizer also faces recurring criticism in modeled AI answers — drug pricing debates, historical settlement exposure (including the $2.3 billion Bextra off-label promotion settlement in 2009, then the largest healthcare fraud settlement in US history), specific drug withdrawals, and the COVID-19 vaccine discourse which includes both ratification and skepticism layers. AI engines composite both signals. Pfizer's AI presence is dominance of the conversation about pharma, not unconditional praise. The same Wikipedia, PubMed, business press, and regulator records that boost Pfizer's visibility also surface the critique. That is how AI synthesis works: it composites the full record, not the brand's preferred narrative.

Pfizer's AI visibility is not built on DTC advertising. It is built on decades of FDA documentation, Wikipedia entry depth, peer-reviewed publication, and primary corporate disclosure. That is the architecture. Most pharma brands have a subset of it. The brands that build all four — across multiple drugs and decades — win the AI conversation about the category.

The pattern is replicable, but the timeframe is long. Most pharma brands do not have a multi-decade FDA portfolio, a dense Wikipedia named-entity graph, or a deep PubMed publication record. The brands that build those three things over time produce pharma AI answers that compound for decades.

Three Findings That Reset Pharma Communications

1. DTC advertising spend does not equal pharma AI visibility. In modeled queries, the brands with the largest DTC television and digital ad budgets are routinely outperformed in AI citation share by brands with deeper FDA documentation, denser Wikipedia presence, and richer PubMed publication records. Pharma is the consumer category where the gap between marketing spend and AI citation share is structurally largest. DTC budgets compound impressions. They do not compound AI references.

2. The brand-vs-generic naming choice is itself an outcome. AI engines choose between brand name (Lipitor) and generic name (atorvastatin) based on documentation depth, Wikipedia presence, and the era of the discussion. Brands that defend their named-entity density during the post-patent transition see their brand mention persist in AI answers; brands that do not see their AI references migrate to the generic compound name. The naming retention strategy is now a meaningful post-LOE (loss of exclusivity) discipline.

3. AI refusal rate is the highest in pharma, and that creates citation scarcity. In our research, AI engines refuse to give specific drug recommendations on roughly 32% of pharma prompts — the highest refusal rate of any consumer category we measure. That refusal creates a smaller pool of answers where brands can surface. The brands that surface in compliant, on-label, evidence-supported framing become disproportionately visible — because the engines are willing to discuss them within their caution settings, when many other brands are filtered out entirely.

The Pharma Brand Playbook

Five moves. Pharma-specific. Compliance-first. Built on the AI Visibility Stack from the hub.

1. Treat FDA documentation as marketing infrastructure. Every approval, labeling update, indication expansion, REMS document, and post-marketing study is a primary record AI engines reference. The FDA-OPDP-compliant publication of accurate drug information is the highest-leverage AI visibility move in pharma. The FDA documentation itself is the marketing.

2. Build and maintain dense Wikipedia entries. Company page, drug pages (each major drug), key executive bios, milestone events. Cross-linked named entities. Verified primary-source citations. Wikipedia is the structural backbone of the AI's pharma narrative. Most pharma companies underinvest in Wikipedia engagement relative to its AI weight.

3. Defend named-entity density across the medical reference layer. Mayo Clinic, Drugs.com, UpToDate, MedlinePlus. These reference sites enter AI answers when buyers ask treatment, side effect, or comparison questions. Accurate, up-to-date drug profiles on these platforms — with brand names defended alongside generics — produce direct AI visibility lift.

4. Sustain the PubMed publication discipline. Phase III trial publications. Post-marketing surveillance studies. Mechanism-of-action research. Comparative effectiveness studies. AI engines weight peer-reviewed publications above all other source types for efficacy and mechanism questions. The publication pipeline is the AI visibility pipeline for the next decade.

5. Treat the brand-vs-generic transition as an AI-visibility event. Loss of exclusivity is a marketing event in the AI era. Brands that fail to defend their named-entity density during and after LOE see AI references migrate to the molecule name within 18 to 36 months. Brands that invest in continued documentation, Wikipedia engagement, and primary-source publication during the transition retain the brand mention longer.

The Misconception

The dominant pharma marketing model still treats DTC advertising — television, digital, magazine — as the primary brand-building lever for consumer-recognized drugs. In 2026, that model produces large impression footprints that do not translate into AI citation share. AI engines do not retrieve from DTC ads. They retrieve from FDA records, Wikipedia, medical references, and peer-reviewed publications.

DTC advertising gets you eyeballs. FDA documentation gets you cited.

A $300 million DTC television campaign does not produce a deeper Wikipedia entry, additional FDA-approved indication documentation, a richer PubMed publication record, or expanded medical reference site coverage. None of those happen by buying impressions. They happen by building the regulator-compliant, peer-reviewed, primary-source documentation layer that pharma AI rewards. The brands that shift attention from impression-buying to source-layer authority will outpace the brands compounding their DTC budgets.

What Pharma Brands Should Measure Quarterly

Pharma AI visibility shifts with new FDA approvals, label updates, clinical trial publications, Wikipedia edits, medical reference site refreshes, and quarterly news cycles. Pharma teams that measure across seven dimensions produce AI answers that move on purpose.

1. FDA primary-record visibility. How often FDA-published records for your drugs surface in modeled AI answers.

2. PubMed mention density. How often your clinical trials and supporting publications appear in modeled answers.

3. Wikipedia entry depth. Company entry + each major drug entry. Updates, primary-source citations, named-entity completeness.

4. Medical reference site frequency. Mayo Clinic, Drugs.com, UpToDate, MedlinePlus. The patient-grade authority layer.

5. Brand-vs-generic naming ratio. In modeled answers about your drug, what percentage of AI references use the brand name vs. the generic compound name? Tracked quarterly through LOE transition.

6. AI refusal rate on category-relevant prompts. What percentage of buyer prompts in your category produce refusal vs. substantive answer? Tracked separately as a category-health signal.

7. Composite citation share across pharma queries. Quarterly five-engine composite for category prompts (drug-class questions, condition-treatment options, branded-vs-generic comparisons).

Together, these seven metrics give a pharma communications team operational precision the discipline has historically lacked outside of media monitoring.

FAQ — Pharma AI Visibility

Related Research

How to Get Inside the ChatGPT Answer Box (hub) · Pfizer Still Owns Pharma AI — The Pharma AI Citation Share Study · How Wellness Brands Win the AI Answer Box · How Crisis PR Wins the AI Answer Box · The AI Platform Citation Source Index 2026

Pharma is the consumer category where regulator-published primary records, peer-reviewed publication discipline, and Wikipedia entry depth outrank DTC budgets in AI answers. The brands that win the answer-engine era treat FDA documentation, scientific publication, and the medical reference layer as the primary communications infrastructure. Everything else is downstream.

The New Pharma Question

For four decades, pharma communications teams asked:

Are we reaching the prescriber and the patient?

In the answer-engine era, the more important question is often:

When buyers and prescribers ask AI engines about our drug — or our drug class — what sources are being synthesized into the answer?

The first question is about reach. The second is about retrieval. Most pharma teams measure the first. The brands building durable pharma AI visibility measure the second too.

This piece is part of the Everything-PR Pharma Pillar. Read the Pharma Citation Share Study 2026 for the modeled ranking of which pharma brands AI engines name first.